Navigation Links
Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use
Date:10/6/2008

Leading Medical Associations Collaborate to Improve Patient Safety

WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- The American College of Cardiology in collaboration with the American College of Gastroenterology and the American Heart Association today released consensus guidelines outlining a stepwise approach for reducing the risk of ulcers and gastrointestinal (GI) bleeding among patients using nonsteroidal anti-inflammatory drugs (NSAIDs) along with antiplatelet agents.

Gastrointestinal bleeding is a major and potentially life-threatening complication for patients taking antiplatelet and NSAID therapy, according to Deepak L. Bhatt, M.D., document co-chair and chief of cardiology, VA Boston Healthcare System. Patients taking low-dose aspirin plus NSAIDs have a two- to four-fold increased risk of gastrointestinal bleeding compared with those not taking these medications.

NSAIDs - the most widely used class of medications in the United States - can reduce fever, pain, and inflammation (swelling and redness). Some are available over the counter (OTC), while others require a prescription. The best-known NSAID is aspirin (which also acts as an antiplatelet agent). Other common NSAIDs are ibuprofen, ketoprofen and naproxen.

Antiplatelet drug treatment, which reduces the blood's ability to clot, is considered a cornerstone in cardiovascular prevention - preventing an event (or subsequent event) in people with atherosclerotic disease. This is usually accomplished by prescribing daily low-dose aspirin. Antiplatelet agents (usually aspirin plus clopidogrel) are also recommended for patients after receiving coronary artery stents to prevent dangerous clotting that could cause a heart attack.

As more Americans survive and live with heart disease in addition to conditions that require them to take NSAIDs (e.g., arthritis, inflammation and related musculoskeletal pain), managing GI risk will become an increasingly important part of card
'/>"/>

SOURCE American College of Gastroenterology; American College of
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. ActivBiotics Outlines a Clinical Path Forward to Examine if Rifalazil Is Superior to Azithromycin in the Treatment of Chlamydia STD
2. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
3. Steps Toward Stopping Autoimmune Disease: International Consortium Identifies Genes Linked to Lupus
4. Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events
5. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
6. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
7. Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants
8. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
9. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
10. American Heart Association Journal Report: Reducing Kids Salt Intake May Lower Soft Drink Consumption, Reducing Obesity, High Blood Pressure and Later Health Risks
11. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 3Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4558 1Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4558 2Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4558 3Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4558 4Micromets Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 4558 5StayWell Custom Communications Announces Strategic Alliance with Siteimprove 48133 1StayWell Custom Communications Announces Strategic Alliance with Siteimprove 48133 2StayWell Custom Communications Announces Strategic Alliance with Siteimprove 48133 3StayWell Custom Communications Announces Strategic Alliance with Siteimprove 48133 4National Marrowthon Campaign Aims to Bring Nearly 50 000 to the Be The Match Registry 28SM 29 in Two Weeks 48131 1National Marrowthon Campaign Aims to Bring Nearly 50 000 to the Be The Match Registry 28SM 29 in Two Weeks 48131 2National Marrowthon Campaign Aims to Bring Nearly 50 000 to the Be The Match Registry 28SM 29 in Two Weeks 48131 3National Marrowthon Campaign Aims to Bring Nearly 50 000 to the Be The Match Registry 28SM 29 in Two Weeks 48131 4